Alkermes units sign settlement and license agreement with Teva
ALKS•Alkermes units and Teva signed an agreement resolving a patent lawsuit over all dosage strengths of Lybalvi. Teva received a U.S. license to sell products under ANDA No. 220379 beginning Nov. 12, 2039.
1. Settlement agreement
Two Alkermes units and Teva entered into a settlement and license agreement on Nov. 6, 2026, resolving a patent lawsuit relating to all dosage strengths of Lybalvi. Teva was granted a license to sell products under ANDA No. 220379 in the United States beginning Nov. 12, 2039. The parties filed a joint stipulation of dismissal with prejudice on Nov. 9, 2026.
